Clinical performance and 5-year retrospective evaluation of Frialit-2 implants.
This retrospective study documents 5 years of clinical experience with Frialit-2 implants. A total of 1,215 implants (338 immediately placed, 877 placed according to a delayed-placement protocol) were placed in 487 patients. After exclusion criteria were applied, 1,099 implants (322 immediate, 777 delayed) in 442 patients remained. The influence of delayed versus immediate placement on the survival of these 1,099 implants was analyzed. The influence of diameter and location (maxilla versus mandible) on survival of the implant were also examined. Implantation sites included anterior and posterior regions; the surgical protocol (ie, immediate or delayed placement) was selected according to the indications for each site. Immediate implants were placed at the time of extraction, while delayed implants were placed 8 to 12 weeks postextraction. A 2-phase surgical protocol was used for all implants. Follow-up time ranged from 5.8 to 67.4 months. According to the Kaplan-Meier method, the cumulative survival rate (CSR) was determined to be 90.05% at 5 years with 103 failures (32 immediate, for a CSR of 90.03%; 71 delayed, for a CSR of 90.04%). The lowest CSR (85%) was seen in the 3.4-mm-wide implants, while the 3.8-mm-wide implants had the highest CSR (93.16%). The CSR for implants in the maxilla was 91.08%; the CSR for implants in the mandible was 89.11%. The CSR was relatively low compared to studies by other authors, who reported on implant populations much smaller than that presented here. A relatively low overall CSR was found, and more than 70% of the failures occurred prior to uncovering (loading) or within 2.5 months of uncovering in this patient population.